These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 10921529)

  • 21. Are centrally acting imidazoline agents appropriate therapy for renovascular hypertension?
    Head GA; Burke SL
    Ann N Y Acad Sci; 2003 Dec; 1009():234-43. PubMed ID: 15028593
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rilmenidine in patients with left ventricular hypertrophy: beyond the reduction of left ventricular mass.
    Trimarco B; Morisco C; Sarno D; Iovino G; Argenziano L; Russo R; De Luca N; Volpe M
    J Cardiovasc Pharmacol; 1995; 26 Suppl 2():S29-33. PubMed ID: 8642802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Haemodynamic and metabolic effects of rilmenidine in hypertensive patients with metabolic syndrome X. A double-blind parallel study versus amlodipine.
    De Luca N; Izzo R; Fontana D; Iovino G; Argenziano L; Vecchione C; Trimarco B
    J Hypertens; 2000 Oct; 18(10):1515-22. PubMed ID: 11057441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rilmenidine: a novel approach to first-line treatment of hypertension.
    Laurent S; Safar M
    Am J Hypertens; 1992 Apr; 5(4 Pt 2):99S-105S. PubMed ID: 1350733
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of hypertension in diabetic patients.
    Lambert AE; Mpoy M; Vandeleene B; Ketelslegers JM
    Am J Med; 1989 Sep; 87(3C):30S-33S. PubMed ID: 2782324
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acceptability of rilmenidine and long-term surveillance of plasma concentrations in hypertensive patients with renal insufficiency.
    Lins RL; Daelemans R; Dratwa M; Verbeelen D; Sennesael J; Brisgand B; Lameire N
    Am J Med; 1989 Sep; 87(3C):41S-45S. PubMed ID: 2782326
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Comparison of the antihypertensive efficacy of and tolerance to 2 imidazoline receptor agonists: moxonidine and rilmenidine in monotherapy].
    Camilleri G; Portal B; Quiniou G; Clerson P
    Ann Cardiol Angeiol (Paris); 2001 Apr; 50(3):169-74. PubMed ID: 12555509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rilmenidine and the high risk hypertensive patient.
    Laragh JH
    Ann N Y Acad Sci; 1995 Jul; 763():634-41. PubMed ID: 7677383
    [No Abstract]   [Full Text] [Related]  

  • 29. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system.
    Scheen AJ
    Drugs; 2004; 64(22):2537-65. PubMed ID: 15516153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rilmenidine: a novel antihypertensive agent.
    Safar ME
    Am J Med; 1989 Sep; 87(3C):24S-29S. PubMed ID: 2571292
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improvement of cardiac diastolic function by long-term centrally mediated sympathetic inhibition in one-kidney, one-clip hypertensive rabbits.
    Signolet IL; Bousquet PP; Monassier LJ
    Am J Hypertens; 2008 Jan; 21(1):54-60. PubMed ID: 18091744
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolic effects of moxonidine and other centrally acting antihypertensives.
    Schachter M
    Diabetes Obes Metab; 1999 Nov; 1(6):317-22. PubMed ID: 11225647
    [No Abstract]   [Full Text] [Related]  

  • 33. Chronic treatment with rilmenidine in spontaneously hypertensive rats: differences between two schedules of administration.
    Monassier L; Greney H; Thomas L; Bousquet P
    J Cardiovasc Pharmacol; 2004 Mar; 43(3):394-401. PubMed ID: 15076223
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Rilmenidine, a new antihypertensive agent in the first line treatment of essential arterial hypertension. Multicenter double-blind study versus atenolol].
    Dallocchio M; Gosse P; Fillastre JP; Grollier G; Morand P; Drici M; Corcoran C
    Presse Med; 1991 Aug 31-Sep 7; 20(27):1265-71. PubMed ID: 1832761
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Actions of rilmenidine on neurogenic hypertension in BPH/2J genetically hypertensive mice.
    Jackson KL; Palma-Rigo K; Nguyen-Huu TP; Davern PJ; Head GA
    J Hypertens; 2014 Mar; 32(3):575-86. PubMed ID: 24275840
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effects of rilmenidine on rats made insulin resistant and hypertensive by a high fructose diet].
    Berthault MF; Morin J; Dubar M; Ktorza A; Ferré P; Pénicaud L
    Arch Mal Coeur Vaiss; 1996 Aug; 89(8):1103-6. PubMed ID: 8949387
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term control of blood pressure by rilmenidine in high-risk populations.
    Pillion G; Fevrier B; Codis P; Schutz D
    Am J Cardiol; 1994 Dec; 74(13):58A-65A. PubMed ID: 7998587
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies.
    Schmieder RE; Martus P; Klingbeil A
    JAMA; 1996 May; 275(19):1507-13. PubMed ID: 8622227
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effects of rilmenidine on the central nervous system and kidney].
    Fillastre JP
    Arch Mal Coeur Vaiss; 1989 Dec; 82 Spec No 5():19-23. PubMed ID: 2517005
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pharmaco-epidemiologic evaluation of rilmenidine in 18,235 hypertensive patients].
    Luccioni R
    Presse Med; 1995 Dec; 24(38):1857-64. PubMed ID: 8545441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.